# Japanese clinical practice guidelines for vascular tumors, vascular malformations, lymphatic malformations, and Lymphangiomatosis 2022

## TL;DR

This paper presents updated clinical guidelines for treating vascular tumors and malformations in Japan, based on evidence-based medicine and systematic reviews.

## Contribution

The paper introduces new evidence-based guidelines for managing vascular anomalies in Japan, covering treatment efficacy and safety.

## Key findings

- The guidelines include 38 clinical questions addressing treatment efficacy and safety.
- Recommendations cover resection, sclerotherapy, drug therapy, and other treatments for vascular anomalies.
- The guidelines emphasize evidence-based approaches and systematic reviews for improved patient outcomes.

## Abstract

The objective was to prepare guidelines to perform the current optimum treatment by organizing effective and efficient treatments of hemangiomas and vascular malformations, confirming the safety, and systematizing treatment, employing evidence‐based medicine techniques and aimed at improvement of the outcomes. Clinical questions (CQs) were decided based on the important clinical issues. For document retrieval, key words for literature searches were set for each CQ and literature published from 1980 to the end of December 2020 was searched in PubMed and Japana Centra Revuo Medicina (JCRM). The strengths of evidence and recommendations acquired by systematic reviews were determined following the Medical Information Network Distribution Service (Minds) technique. A total of 38 CQs were used to compile recommendations and the subjects included efficacy of resection, sclerotherapy/embolization, drug therapy, laser therapy, radiotherapy, and other conservative treatment, differences in appropriate treatment due to the location of lesions and among symptoms, appropriate timing of treatment and tests, pathological diagnosis deciding the diagnosis, and causal genes of vascular anomalies. Thus, the Japanese Clinical Practice Guidelines for Vascular Tumors, Vascular Malformations, Lymphatic Malformations, and Lymphangiomatosis 2022 have been prepared as the evidence‐based guidelines for the management of vascular anomalies.